TWI624474B - 類毒素、組合物及相關方法 - Google Patents

類毒素、組合物及相關方法 Download PDF

Info

Publication number
TWI624474B
TWI624474B TW103110044A TW103110044A TWI624474B TW I624474 B TWI624474 B TW I624474B TW 103110044 A TW103110044 A TW 103110044A TW 103110044 A TW103110044 A TW 103110044A TW I624474 B TWI624474 B TW I624474B
Authority
TW
Taiwan
Prior art keywords
toxoid
toxin
formaldehyde
composition
purified
Prior art date
Application number
TW103110044A
Other languages
English (en)
Chinese (zh)
Other versions
TW201514197A (zh
Inventor
史蒂芬 豪瑟
Original Assignee
賽諾菲巴斯德有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 賽諾菲巴斯德有限公司 filed Critical 賽諾菲巴斯德有限公司
Publication of TW201514197A publication Critical patent/TW201514197A/zh
Application granted granted Critical
Publication of TWI624474B publication Critical patent/TWI624474B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
TW103110044A 2013-03-15 2014-03-17 類毒素、組合物及相關方法 TWI624474B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361790423P 2013-03-15 2013-03-15
US61/790,423 2013-03-15

Publications (2)

Publication Number Publication Date
TW201514197A TW201514197A (zh) 2015-04-16
TWI624474B true TWI624474B (zh) 2018-05-21

Family

ID=50489430

Family Applications (1)

Application Number Title Priority Date Filing Date
TW103110044A TWI624474B (zh) 2013-03-15 2014-03-17 類毒素、組合物及相關方法

Country Status (13)

Country Link
US (2) US20160045586A1 (cg-RX-API-DMAC7.html)
EP (1) EP2968507A2 (cg-RX-API-DMAC7.html)
JP (1) JP2016516721A (cg-RX-API-DMAC7.html)
KR (1) KR20150133770A (cg-RX-API-DMAC7.html)
CN (1) CN105338997A (cg-RX-API-DMAC7.html)
AR (1) AR095669A1 (cg-RX-API-DMAC7.html)
AU (1) AU2014228956A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015023332A2 (cg-RX-API-DMAC7.html)
CA (1) CA2907154A1 (cg-RX-API-DMAC7.html)
HK (1) HK1213800A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201507608PA (cg-RX-API-DMAC7.html)
TW (1) TWI624474B (cg-RX-API-DMAC7.html)
WO (1) WO2014144567A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR086199A1 (es) 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
SG11201510166YA (en) 2013-06-14 2016-01-28 Sanofi Pasteur Inc Compositions and methods of immunizing against c. difficile
BR112017024443A2 (pt) * 2015-05-15 2018-10-23 Sanofi Pasteur Inc métodos para imunização contra clostridium difficile
MX388528B (es) 2017-06-09 2025-03-20 Hipra Scient S L U Vacuna que comprende toxoides de clostridium.
US10096313B1 (en) * 2017-09-20 2018-10-09 Bose Corporation Parallel active noise reduction (ANR) and hear-through signal flow paths in acoustic devices
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
EP4444742A4 (en) * 2021-12-06 2025-12-10 Univ Rutgers Compositions and Methods for Treating Cancer
EP4658302A1 (en) 2023-02-02 2025-12-10 GlaxoSmithKline Biologicals S.A. Immunogenic composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999020304A1 (en) * 1997-10-20 1999-04-29 Oravax, Inc. Passive immunization against clostridium difficile disease
WO2009035707A1 (en) * 2007-09-14 2009-03-19 Acambis Inc. Pharmaceutical compositions containing clostridium difficile toxoids a and b

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
US5610023A (en) * 1995-03-31 1997-03-11 Lee Laboratories, Inc. Method of purification of clostridium difficile toxin A and production of mono-specific antibodies
US6969520B2 (en) * 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
US6669520B2 (en) 2001-09-19 2003-12-30 United Microelectronics Corp. Method of fabricating an LC panel
JP2010534622A (ja) 2007-07-26 2010-11-11 サノフィ パストゥール リミテッド 抗原−アジュバント組成物および方法
GB201011968D0 (en) * 2010-07-16 2010-09-01 Secr Defence Toxoiding method

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999020304A1 (en) * 1997-10-20 1999-04-29 Oravax, Inc. Passive immunization against clostridium difficile disease
WO2009035707A1 (en) * 2007-09-14 2009-03-19 Acambis Inc. Pharmaceutical compositions containing clostridium difficile toxoids a and b

Also Published As

Publication number Publication date
KR20150133770A (ko) 2015-11-30
EP2968507A2 (en) 2016-01-20
CA2907154A1 (en) 2014-09-18
JP2016516721A (ja) 2016-06-09
SG11201507608PA (en) 2015-10-29
WO2014144567A2 (en) 2014-09-18
TW201514197A (zh) 2015-04-16
WO2014144567A3 (en) 2014-12-04
US20160045586A1 (en) 2016-02-18
BR112015023332A2 (pt) 2017-08-22
HK1213800A1 (zh) 2016-07-15
CN105338997A (zh) 2016-02-17
AR095669A1 (es) 2015-11-04
US20180028637A1 (en) 2018-02-01
AU2014228956A1 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
US20180028637A1 (en) Toxoid, Compositions and Related Methods
CN102238960B (zh) 制造疫苗的方法
EP3310381B1 (en) Immunogenic compositions
KR20180054629A (ko) 장외 병원성 e. 콜리에 대한 면역 보호를 위한 방법 및 조성물
Alves et al. Clostridium septicum: A review in the light of alpha-toxin and development of vaccines
KR20160020543A (ko) 씨. 디피실에 대해서 면역화시키는 조성물 및 방법
US20180000918A1 (en) Vaccine compositions for use against enterotoxigenic escherichia coli
JP2015528457A (ja) Staphylococcusaureusに対する免疫化のための安定化されたタンパク質
AU2018204879A1 (en) Toxoid, compositions and related methods
JP2016519671A5 (cg-RX-API-DMAC7.html)
US20180110849A1 (en) Methods for immunizing against clostridium difficile
DK2376113T3 (en) PREPARATIONS AND DOSAGE REGIMES WHICH INCLUDES A CLOSTRIDIUM VACCINE AND levamisole
CN111467488A (zh) 一种水溶性复合免疫佐剂及其应用
JP2015532594A (ja) Staphylococcusaureusに対する免疫化のための安定化されたタンパク質
RU2526570C2 (ru) Вакцина против ящура типа а инактивированная сорбированная
EP0563288B1 (en) Immunopotentiation of vaccines, particularly swine pleuropneumonia vaccines
RU2699035C2 (ru) Поливалентная вакцина против анаэробной энтеротоксемии молодняка крупного рогатого скота и способ ее применения
HK40093842A (en) Immunogenic compositions
Kumar et al. Immunological studies on a modified multiple emulsion (w/o/w) bivalent Haemmorhagic septicemia vaccine incorporated with Pasteurella multocida P52 in the external aqueous phase
WO2011131208A1 (fr) Vaccin bivalent a usage vétérinaire anti-entérotoxémie

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees